SanBio Company Limited (SNBIF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
SanBio Company Limited (SNBIF) trades at $16.45 with AI Score 48/100 (Grade C). SanBio Company Limited is a Tokyo-based biopharmaceutical firm specializing in regenerative cell therapies for central nervous system disorders. Market cap: $1.28B, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for SNBIF: SNBIF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SNBIF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SNBIF: 2/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
SanBio Company Limited (SNBIF) Healthcare & Pipeline Overview
SanBio Company Limited is a Tokyo-based biopharmaceutical firm focused on regenerative cell therapies for central nervous system disorders. With its lead product, SB623, having completed Phase 2 trials for traumatic brain injury, the company is advancing a diverse pipeline targeting neurological, ocular, and muscular conditions, positioning itself in the innovative biotechnology sector.
What Is the Investment Thesis for SNBIF?
SanBio Company Limited presents a research-grade thesis centered on its advanced regenerative cell therapy pipeline, particularly SB623. The successful completion of Phase 2 clinical trials for SB623 in traumatic brain injury (TBI) in both the U.S. and Japan signifies a crucial de-risking event and a potential catalyst for future development. The company's broad pipeline, including SB623 for multiple CNS and ocular conditions, along with SB618, SB308, MSC1, and MSC2 for other indications, demonstrates a diversified approach to therapeutic innovation. With a market capitalization of $1.28B and a Beta of 0.28, the company exhibits a relatively stable profile within the often-volatile biotechnology sector. Key value drivers include potential progression to Phase 3 trials for SB623, successful clinical outcomes for other pipeline assets, and eventual regulatory approvals. However, inherent risks in biotechnology, such as clinical trial failures, regulatory hurdles, and intense competition, must be considered. The company's small employee base of 29 suggests a lean operational structure focused on specialized R&D.
Based on FMP financials and quantitative analysis
SNBIF Key Highlights
Market Capitalization: $1.28 billion, positioning it as a mid-cap player in the biotechnology sector.
- Beta: 0.28, indicating lower volatility compared to the broader market, which is notable for a biotech firm.
- Employee Count: 29 employees, suggesting a highly specialized and focused research and development team.
- Lead Product Advancement: SB623 has successfully completed Phase 2 clinical trials for traumatic brain injury in both the United States and Japan.
- Diverse Pipeline: The company maintains a broad therapeutic pipeline, including SB623 for multiple CNS disorders, SB618 for peripheral nerve damage, SB308 for muscular dystrophy, MSC1 for cancer, and MSC2 for inflammatory diseases.
Who Are SNBIF's Competitors?
SNBIF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| LBRX LB Pharmaceuticals Inc | $47.23 | -3.49% | $1.35B | 74 |
| MGTX MeiraGTx Holdings plc | $14.86 | -0.74% | $1.38B | 72 |
| INVA Innoviva, Inc. | $21.04 | -2.05% | $1.55B | 94 |
| CVAC CureVac N.V. | $4.66 | +0.00% | $1.05B | 71 |
| ETON Eton Pharmaceuticals, Inc. | $59.91 | -2.55% | $1.64B | 98 |
| VERV Verve Therapeutics, Inc. | $11.13 | +0.27% | $994M | 71 |
| CLYM Climb Bio, Inc. | $17.02 | -1.85% | $975M | 76 |
| ABUS Arbutus Biopharma Corporation | $4.77 | -4.22% | $942M | 83 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SNBIF's Key Strengths?
Lead product SB623 has successfully completed Phase 2 clinical trials for TBI in major markets.
- Diverse pipeline targeting multiple high-unmet-need conditions beyond TBI, including stroke, Parkinson's, and cancer.
- Specialized focus on regenerative cell therapies, a cutting-edge area of biotechnology.
- Established in 2001, indicating a long-standing commitment to its core mission.
What Are SNBIF's Weaknesses?
Small employee base of 29, which may limit the scale and speed of multiple concurrent clinical programs.
- Reliance on a single lead product (SB623) for near-term value creation, despite a broader pipeline.
- Operating in a highly capital-intensive industry with long development cycles and high failure rates.
- Currently trades on the OTC market, which can imply lower liquidity and transparency.
What Could Drive SNBIF Stock Higher?
SNBIF catalyst: Initiation of Phase 3 clinical trials for SB623 in traumatic brain injury (TBI) in the U.S. and Japan, which would signify significant progress towards market entry.
- Announcement of positive interim or final results from ongoing clinical trials for SB623 in other indications such as stroke or neurodegenerative diseases.
- Successful achievement of regulatory milestones, such as Fast Track designation or Breakthrough Therapy designation, for any of its pipeline candidates.
- Formation of strategic partnerships or licensing agreements with larger pharmaceutical companies to support further development or commercialization of its therapies.
What Are the Key Risks for SNBIF?
Negative return on equity (-44.8%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or unexpected adverse events in later-stage trials for SB623 or other pipeline candidates, which could halt development and result in significant financial losses.
- Stringent and evolving regulatory hurdles in major markets, potentially leading to delays in approvals or outright rejection of therapies.
- Intense competition from other biotechnology and pharmaceutical companies developing similar or alternative treatments for central nervous system disorders and other target indications.
- Challenges in securing sufficient funding for the extensive and capital-intensive research, development, and commercialization phases inherent in the biotechnology industry.
- Risks associated with trading on the OTC market, including lower liquidity, limited transparency, and potential for price volatility, which may impact investor confidence and valuation.
What Are the Growth Opportunities for SNBIF?
- Growth opportunity 1: Advancement of SB623 for Traumatic Brain Injury (TBI). The successful completion of Phase 2 trials for SB623 in both the U.S. and Japan for TBI represents a significant milestone. The global market for TBI treatments is substantial, with millions affected annually and limited effective long-term solutions. Progression to Phase 3 trials and subsequent regulatory approval would unlock a significant revenue stream, establishing SanBio as a leader in regenerative therapy for neurological trauma. The timeline for such development typically spans several years, requiring substantial investment in further clinical studies and manufacturing scale-up.
- Growth opportunity 2: Expansion of SB623's therapeutic indications. Beyond TBI, SanBio is exploring SB623 for a range of other central nervous system disorders, including ischemic and hemorrhagic strokes, Parkinson's disease, and Alzheimer's disease. Each of these represents a vast market with high unmet medical needs. For instance, stroke is a leading cause of long-term disability globally. Positive results from ongoing or future clinical trials in these indications could dramatically expand the total addressable market for SB623, providing multiple potential revenue streams and diversifying the company's product portfolio over the next 5-10 years.
- Growth opportunity 3: Development of SB618 for peripheral nerve damage. Peripheral nerve damage affects millions worldwide due to injury, disease, or surgery, often leading to chronic pain and functional impairment. Current treatment options are often insufficient. SB618, as a regenerative cell therapy, could offer a novel approach to repair damaged nerves and restore function. Successful clinical development and commercialization of SB618 would tap into a distinct but related market opportunity, leveraging SanBio's expertise in regenerative medicine. This pipeline asset could provide a new growth vector within the next 7-12 years.
- Growth opportunity 4: Exploration of MSC1 for cancer treatment. SanBio's development of MSC1 for cancer represents a strategic diversification into oncology, a market segment with immense potential and continuous demand for innovative therapies. Mesenchymal stem cells (MSCs) are being investigated for their immunomodulatory and anti-tumor properties. If MSC1 demonstrates efficacy in clinical trials, it could position SanBio in a highly lucrative and competitive market, potentially offering a new therapeutic modality for various cancer types. This is a longer-term growth opportunity, likely requiring extensive preclinical and clinical development over the next decade.
- Growth opportunity 5: Development of MSC2 for inflammatory diseases and optic neuritis. Inflammatory diseases encompass a broad range of conditions, many of which are chronic and debilitating, while optic neuritis can lead to significant vision loss. MSC2, as a regenerative cell therapy, could address the underlying inflammation and promote tissue repair. Success in these indications would open up new therapeutic areas for SanBio, leveraging the anti-inflammatory and regenerative properties of MSCs. This represents another significant market opportunity, with development timelines typically extending over several years, potentially yielding results in the next 5-10 years.
What Are SNBIF's Competitive Advantages?
- Proprietary regenerative cell therapy platform and intellectual property surrounding SB623 and other pipeline candidates.
- Advanced clinical development stage of SB623 (Phase 2 completion for TBI), providing a lead over potential new entrants.
- Specialized expertise in central nervous system disorders, a complex and high-barrier-to-entry therapeutic area.
- Regulatory know-how and experience navigating the approval processes in key markets like the U.S. and Japan.
- Potential for first-in-class or best-in-class therapies addressing significant unmet medical needs.
What Does SNBIF Do?
SanBio Company Limited, established in 2001 and headquartered in Tokyo, Japan, is a biopharmaceutical firm dedicated to the development, manufacture, and commercialization of regenerative cell therapies. The company's core focus lies in addressing disorders of the central nervous system, a therapeutic area with significant unmet medical needs. A cornerstone of SanBio's product portfolio is SB623, a regenerative cell medicine that has successfully completed Phase 2 clinical trials for the treatment of traumatic brain injury (TBI) in both the United States and Japan. This achievement represents a critical milestone in its development pathway, demonstrating potential efficacy and safety in a complex neurological condition. Beyond TBI, SanBio is actively exploring the therapeutic potential of SB623 across a wide array of other challenging conditions. Its research pipeline for SB623 includes investigations into ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, and Alzheimer's disease. This broad application strategy underscores the company's commitment to leveraging its core technology for diverse neurological and ocular indications. In addition to SB623, SanBio is expanding its therapeutic offerings with other distinct candidates. These include SB618, which is under development for peripheral nerve damage; SB308, targeting muscular dystrophy; MSC1, being explored as a treatment for various cancers; and MSC2, aimed at inflammatory diseases and optic neuritis. With a team of 29 employees, SanBio maintains a focused approach on advancing its specialized regenerative medicine pipeline from research and development through to potential commercialization.
What Products and Services Does SNBIF Offer?
- Develop regenerative cell therapies primarily for central nervous system disorders.
- Conduct clinical trials for lead product SB623, which has completed Phase 2 for traumatic brain injury.
- Research SB623's potential for ischemic and hemorrhagic strokes, Parkinson's, Alzheimer's, and ocular conditions.
- Develop SB618 for peripheral nerve damage, expanding into non-CNS neurological applications.
- Advance SB308 for muscular dystrophy, addressing genetic muscle disorders.
- Investigate MSC1 as a regenerative cell therapy candidate for various cancers.
- Develop MSC2 for inflammatory diseases and optic neuritis, targeting immune-mediated conditions.
- Manufacture and commercialize their proprietary regenerative cell medicines.
How Does SNBIF Make Money?
- Focus on research and development of novel regenerative cell therapies.
- Seek regulatory approvals for developed therapies to enable market entry.
- Potentially license out or partner with larger pharmaceutical companies for commercialization and distribution.
- Generate revenue through sales of approved regenerative cell products.
- Secure funding through equity financing or collaborations to support extensive R&D cycles.
What Industry Does SNBIF Operate In?
SanBio Company Limited operates within the highly specialized and rapidly evolving biotechnology industry, specifically focusing on regenerative cell therapies for central nervous system disorders. This sector is characterized by extensive research and development, long clinical trial timelines, and significant regulatory hurdles. The global regenerative medicine market is experiencing substantial growth, driven by advancements in cell biology, increasing prevalence of chronic diseases, and rising demand for innovative treatments where conventional therapies are limited. SanBio's focus on conditions like TBI, stroke, and neurodegenerative diseases positions it within a segment addressing high unmet medical needs. The competitive landscape includes both large pharmaceutical companies with significant R&D budgets and smaller, specialized biotech firms. SanBio differentiates itself through its specific focus on regenerative cell therapies and the advanced clinical stage of its lead candidate, SB623, in a challenging therapeutic area.
Who Are SNBIF's Key Customers?
- Patients suffering from traumatic brain injury and other central nervous system disorders.
- Patients with peripheral nerve damage, muscular dystrophy, cancer, and inflammatory diseases.
- Neurologists, neurosurgeons, ophthalmologists, and other medical specialists who prescribe advanced therapies.
- Hospitals and clinics specializing in regenerative medicine and neurological care.
- Healthcare systems seeking innovative treatments for challenging conditions.
Forward Outlook
Wall Street analysts project SanBio Company Limited revenue of about $254.7M for fiscal 2026, with EPS near $-53.83. The estimate reflects 3 contributing analysts.
Earnings Track Record
SanBio Company Limited has beaten Wall Street's EPS estimate in 5 of its last 6 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 19.6% above estimates on average.
Financial Health
SanBio Company Limited's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 66.58 places it in the safe zone, indicating low near-term bankruptcy risk.
Key Financial Metrics
Return on equity for SanBio Company Limited stands at -44.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -21.7%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 53.00 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -4.1%, the inverse of the P/E and a quick read on earnings relative to price.
SanBio Company Limited (SNBIF) Valuation Context
Valued at $1.28B, SNBIF is classified as a small-cap stock. Relative to its peer group, SNBIF's quantitative score of 48/100 is below the peer average of 82/100.
Company Profile
SanBio Company Limited operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Tokyo, JP. The company is led by CEO Keita Mori. SNBIF has traded publicly since 2015.
SNBIF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- SanBio's regenerative medicine approach is gaining traction, with potential breakthroughs in neurological disorders. This could lead to significant long-term growth, similar to the early excitement around gene therapy companies.
- Recent insider buying suggests confidence in the company's future prospects, signaling that those closest to the business see value. This echoes situations like when executives loaded up on Apple stock before major product launches.
- Positive community sentiment indicates growing awareness and belief in SanBio's technology and its potential to address unmet medical needs. This groundswell of support can be a powerful driver.
- The increasing focus on regenerative medicine within the broader healthcare industry is creating a favorable environment for companies like SanBio, mirroring the tailwinds that propelled renewable energy companies.
Bear Case
- Regulatory hurdles and the lengthy approval process for regenerative medicine products pose significant challenges, potentially delaying commercialization. This is a common pitfall for biotech companies, like the delays faced by some gene editing firms.
- Negative community sentiment surrounding past clinical trial results raises concerns about the efficacy and safety of SanBio's products, impacting investor confidence. This is similar to the skepticism faced by some pharmaceutical companies after trial setbacks.
- Market perception of SanBio as a high-risk, high-reward investment makes it vulnerable to market volatility and shifts in investor sentiment. This mirrors the boom-and-bust cycles seen in the cannabis industry.
- Limited market visibility and awareness outside of specialized biotech circles hinder broader investor interest, potentially capping the company's growth potential. This is a challenge faced by many small-cap biotech companies.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
SNBIF Latest News
No recent news available for SNBIF.
SNBIF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SNBIF.
Price Targets
Wall Street price target analysis for SNBIF.
SNBIF MoonshotScore
What does this score mean?
The MoonshotScore rates SNBIF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Keita Mori
Chief Executive Officer
Keita Mori serves as the Chief Executive Officer of SanBio Company Limited, leading a specialized team of 29 employees in the biopharmaceutical sector. While specific details of his educational background are not provided, his leadership role in a company focused on advanced regenerative cell therapies suggests a strong foundation in the healthcare or life sciences industry, potentially complemented by extensive experience in corporate management and strategic development within the biotechnology space. His tenure at SanBio has been instrumental in guiding the company's research and development efforts, particularly in the complex field of central nervous system disorders.
Track Record: Under Keita Mori's leadership, SanBio Company Limited has achieved a significant milestone with its lead product, SB623, successfully completing Phase 2 clinical trials for traumatic brain injury in both the United States and Japan. This accomplishment underscores his strategic direction in advancing the company's core therapeutic assets through critical development stages. His management has also overseen the expansion of SanBio's pipeline to include multiple regenerative cell therapy candidates targeting diverse conditions, demonstrating a commitment to broad therapeutic innovation and long-term growth.
SNBIF OTC Market Information
SanBio Company Limited trades on the OTC market under the 'OTC Other' tier. This tier typically includes companies that do not meet the disclosure or financial standards for higher OTC tiers like OTCQX or OTCQB, nor do they trade on major exchanges such as the NYSE or NASDAQ. Companies in the 'OTC Other' tier often have limited public information available, making comprehensive due diligence more challenging for investors. This classification generally indicates less stringent reporting requirements and lower transparency compared to exchange-listed securities, which can impact investor confidence and market perception.
- OTC Tier: OTC Other
- Limited Transparency: 'OTC Other' companies often have less stringent reporting requirements, leading to a lack of comprehensive and timely financial and operational disclosures.
- Lower Liquidity: Reduced trading volume and wider bid-ask spreads can make it difficult to buy or sell shares efficiently, potentially leading to price volatility.
- Price Manipulation Risk: Less regulatory oversight and transparency can make OTC stocks more susceptible to pump-and-dump schemes or other forms of market manipulation.
- Delisting Risk: Companies in lower OTC tiers face a higher risk of being delisted or becoming untradeable if they fail to meet even minimal requirements or cease operations.
- Limited Analyst Coverage: OTC stocks typically receive little to no coverage from institutional analysts, making it harder for investors to access independent research and valuation insights.
- Verify the company's current financial statements and audit reports, if available, directly from the company or regulatory filings.
- Research the background and track record of the management team, including any past regulatory issues or controversies.
- Thoroughly understand the company's business operations, product pipeline, and market position, seeking third-party validation where possible.
- Investigate any legal or regulatory actions against the company or its executives.
- Assess the company's capital structure, outstanding shares, and potential for dilution from future offerings.
- Review any available news, press releases, or investor presentations for recent developments and strategic direction.
- Understand the specific risks associated with the biotechnology industry and the regenerative medicine sector.
- Established Founding Year: Founded in 2001, indicating a long operational history in the biotechnology sector.
- Specific Product Pipeline: Clearly defined lead product (SB623) with documented Phase 2 clinical trial completion for TBI.
- Named CEO: Keita Mori is identified as the Chief Executive Officer, providing accountability and leadership visibility.
- Headquartered in Tokyo, Japan: A specific and established geographic location for its operations.
- Focus on a Specialized Industry: Dedicated to regenerative cell therapies for CNS disorders, demonstrating a clear, high-tech business focus.
SNBIF Healthcare Stock FAQ
What does the AI Score mean for SNBIF?
SNBIF holds an AI Score of 48/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. SanBio Company Limited is a Tokyo-based biopharmaceutical firm specializing in regenerative cell therapies for central nervous system disorders. Its lead product, SB623, has completed Phase 2 …
What does SanBio Company Limited do?
SanBio Company Limited is a biopharmaceutical firm based in Tokyo, Japan, specializing in the development, manufacture, and commercialization of regenerative cell therapies. Its primary focus is on addressing disorders of the central nervous system, including traumatic brain injury (TBI), stroke, Parkinson's, and Alzheimer's disease, with its lead product SB623 having completed Phase 2 clinical trials for TBI.
What is SanBio Company Limited's drug pipeline status?
SanBio Company Limited's drug pipeline is centered around its lead regenerative cell therapy, SB623, which has successfully completed Phase 2 clinical trials for traumatic brain injury (TBI) in both the United States and Japan. This positions SB623 for potential progression into Phase 3 trials.
What are the main risks for SNBIF?
The main risks for SNBIF include the inherent uncertainties of clinical development, such as potential failures in future clinical trials (e.g., Phase 3 for SB623) or unexpected adverse events, which could lead to significant delays or discontinuation of product development. Regulatory risks are also substantial, as stringent and evolving requirements from health authorities could impede or prevent market approvals.
What are the key factors to evaluate for SNBIF?
SanBio Company Limited (SNBIF) holds an AI score of 48/100 (low). SanBio Company Limited presents a research-grade thesis centered on its advanced regenerative cell therapy pipeline, particularly SB623. Not financial advice.
How frequently does SNBIF data refresh on this page?
SNBIF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SNBIF's recent stock price performance?
SanBio Company Limited (SNBIF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Lead product SB623 has successfully completed Phase 2 clinical trials for TBI in major markets. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SNBIF overvalued or undervalued right now?
SanBio Company Limited (SNBIF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SNBIF before investing?
Before investing in SanBio Company Limited (SNBIF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.